Lv1
80 积分 2025-01-12 加入
Radiotherapy, immunity, and immune checkpoint inhibitors
11小时前
待确认
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
1个月前
已完结
Towards targeting the breast cancer immune microenvironment
1个月前
已完结
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
2个月前
已完结
LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
2个月前
已关闭
LBA10 Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC)
2个月前
已关闭
TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design
2个月前
已完结
Phase I/II study of stereotactic body radiation therapy (SBRT) to metastatic lesions in the liver or lung in combination with monoclonal antibody to OX40 in patients with progressive metastatic breast cancer (mBC) after systemic therapy
2个月前
已关闭
Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors
2个月前
已关闭
Abstract CT120: Phase II study of radiotherapy in combination with chemotherapy and immunotherapy in patients with PD-L1-positive metastatic triple-negative breast cancer
2个月前
已关闭
皖公网安备34019202002308
